← Back to Search

Behavioural Intervention

Cognitive Behavioral Therapy for Insomnia in Multiple Sclerosis (CALM Trial)

Phase 2
Recruiting
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged between 18-65 years old
Diagnosis of relapsing-remitting or secondary progressive MS verified by neurologist
Must not have
Known untreated sleep disorder (such as sleep apnea or restless legs syndrome)
History of other nervous system disorder such as stroke or Parkinson's disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 6, month 6
Awards & highlights

Summary

This trial aims to study the effectiveness of cognitive behavioral therapy for insomnia (CBT-I) in improving insomnia symptoms, fatigue, and quality of life in individuals with multiple sclerosis. Insomnia is a common

Who is the study for?
This trial is for individuals aged 18-65 with relapsing-remitting or secondary progressive Multiple Sclerosis who experience insomnia symptoms at least three nights a week for the past three months. Participants should have mild-to-moderate disability, be English-speaking, and have internet access plus a suitable device.
What is being tested?
The study aims to test if Cognitive Behavioral Therapy for Insomnia (CBT-I) can improve sleep, reduce fatigue, and enhance quality of life in MS patients compared to an active control group that receives only sleep and lifestyle education.
What are the potential side effects?
Since CBT-I is a non-pharmacological therapy focusing on changing thoughts and behaviors around sleep, it typically does not involve physical side effects. However, some may experience temporary increases in anxiety or frustration as they adjust to new sleeping habits.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.
Select...
My MS has been confirmed as relapsing-remitting or secondary progressive by a neurologist.
Select...
My disability level is mild to moderate.
Select...
I've had trouble sleeping at least 3 nights a week for the last 3 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have an untreated sleep disorder like sleep apnea or restless legs syndrome.
Select...
I have a history of a nervous system disorder like stroke or Parkinson's.
Select...
I am currently undergoing treatment for sleep issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 6, month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 6, month 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Insomnia Severity Index (ISI)
Secondary outcome measures
Actigraphy
Cognitive Failures Questionnaire (CFQ)
Dysfunctional Beliefs About Sleep
+7 more
Other outcome measures
Adherence to CBT-I intervention
Diet quality
Eating regularity
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Cognitive behavioral therapy for insomniaExperimental Treatment1 Intervention
1x/week, 6-week 45-60 min one-one-one manualized program via video conferencing (HIPAA-compliant Zoom) with a trained research assistant that includes time in bed restriction, stimulus control, relaxation strategies, cognitive restructuring, and sleep health promotion education.
Group II: Sleep and lifestyle educationActive Control1 Intervention
1x/week, 6 weekly 45-60 min one-on-one program via video conferencing (HIPAA-compliant Zoom) with a trained research assistant that includes gentle stretching activities for major muscle groups accompanied by sleep and lifestyle education.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive behavioral therapy for insomnia
2013
Completed Phase 3
~810

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
488 Previous Clinical Trials
172,385 Total Patients Enrolled
8 Trials studying Multiple Sclerosis
483 Patients Enrolled for Multiple Sclerosis
~47 spots leftby May 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top